Show simple item record

dc.contributor.advisorMatthews, Kellyen
dc.contributor.advisorLawler, Laurenen
dc.contributor.advisorSlack, Marionen
dc.contributor.authorNavoa, Gabriel
dc.contributor.authorEljerdi, Osama
dc.contributor.authorHuo, Ye
dc.date.accessioned2017-06-15T17:11:20Z
dc.date.available2017-06-15T17:11:20Z
dc.date.issued2017
dc.identifier.urihttp://hdl.handle.net/10150/624171
dc.descriptionClass of 2017 Abstracten
dc.description.abstractObjectives: Medication adherence tools and technologies can have a significant impact on the level of drug therapy continuation as well as improved outcomes. The RxTimerCap© is a device that aims to act as a medication adherence cap with an embedded timer to indicate the time since the medication was last taken. Our aim was to assess if this cap technology would aid in increased drug adherence and duration of therapy with abiraterone (Zytiga®). Methods: The study was a prospective, single-center, interventional study that included males 18 or older being treated with Zytiga for castration-resistant metastatic prostate cancer. Medication possession ratio (MPR) and duration on therapy were the primary measures used to assess if there would be improved adherence. Paired t- tests were used to analyze the data and assess the significance of the outcomes. Results: There was no significant difference between patients in MPR (p = 0.50) or in the duration of treatment (p = 0.20). Conclusions: The difference in adherence rates for patients using the RxTimerCap© and those using the standard vial cap were non-significant. The limited size of our study population and short study duration may have led to these undifferentiated outcomes. Future studies should examine this type of adherence technology in a larger sample of patients with a prolonged window of observation to better assess the benefits of using the RxTimerCap©.
dc.language.isoen_USen
dc.publisherThe University of Arizona.en
dc.rightsCopyright © is held by the author.en
dc.subjectPatient Medication Adherenceen
dc.subjectTechnologyen
dc.subjectRxTimerCap©en
dc.subject.meshMedication Adherenceen
dc.subject.meshTechnology, Pharmaceuticalen
dc.titleThe Effects of Using the RxTimerCap© on Patient Medication Adherenceen_US
dc.typetexten
dc.typeElectronic Reporten
dc.contributor.departmentCollege of Pharmacy, The University of Arizonaen
dc.description.collectioninformationThis item is part of the Pharmacy Student Research Projects collection, made available by the College of Pharmacy and the University Libraries at the University of Arizona. For more information about items in this collection, please contact Jennifer Martin, Associate Librarian and Clinical Instructor, Pharmacy Practice and Science, jenmartin@email.arizona.edu.en
refterms.dateFOA2018-08-13T19:25:02Z
html.description.abstractObjectives: Medication adherence tools and technologies can have a significant impact on the level of drug therapy continuation as well as improved outcomes. The RxTimerCap© is a device that aims to act as a medication adherence cap with an embedded timer to indicate the time since the medication was last taken. Our aim was to assess if this cap technology would aid in increased drug adherence and duration of therapy with abiraterone (Zytiga®). Methods: The study was a prospective, single-center, interventional study that included males 18 or older being treated with Zytiga for castration-resistant metastatic prostate cancer. Medication possession ratio (MPR) and duration on therapy were the primary measures used to assess if there would be improved adherence. Paired t- tests were used to analyze the data and assess the significance of the outcomes. Results: There was no significant difference between patients in MPR (p = 0.50) or in the duration of treatment (p = 0.20). Conclusions: The difference in adherence rates for patients using the RxTimerCap© and those using the standard vial cap were non-significant. The limited size of our study population and short study duration may have led to these undifferentiated outcomes. Future studies should examine this type of adherence technology in a larger sample of patients with a prolonged window of observation to better assess the benefits of using the RxTimerCap©.


Files in this item

Thumbnail
Name:
GabeOsamaYoFinalReport2008-09- ...
Size:
761.9Kb
Format:
PDF
Description:
Final Report

This item appears in the following Collection(s)

Show simple item record